Formulations for treatment of dry eye disease
US11197821B2 · kind B2 · utility
12Cited by
38References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 25, 2019 |
| Grant date | Dec 14, 2021 |
| Priority date | — |
| Expiry date | Jan 12, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating dry eye disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.